Related Experiment Video

Updated: Aug 13, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 18, 2014

Early pulmonary disease in cystic fibrosis

F J Accurso1

  • 1Children's Hospital, Denver, CO 80218, USA.

Current Opinion in Pulmonary Medicine
|December 10, 1997
PubMed

Insights

Early intervention for cystic fibrosis (CF) in infants is crucial. Research is developing methods to assess lung function and airway health in young children to enable trials aimed at preventing progressive lung disease.

Area of Science:

  • Pulmonology
  • Pediatric Medicine
  • Genetics

Background:

  • Cystic fibrosis (CF) leads to progressive lung disease driven by airway infection and inflammation.
  • Evidence suggests CF pathogenesis begins in early childhood, yet optimal early treatment remains unclear.
  • Current treatments for young CF patients mirror those for adults, but their efficacy in preventing disease progression is not well-established.

Purpose of the Study:

  • To investigate the potential of early treatment to delay or prevent progressive lung disease in young cystic fibrosis patients.
  • To highlight the need for robust outcome measures for interventional trials in infants and young children with CF.

Main Methods:

  • Review of current treatment approaches for respiratory symptoms in young cystic fibrosis patients.
  • Discussion of emerging outcome measures for infant lung function, imaging, and lower airway sampling (e.g., bronchoalveolar lavage).
  • Emphasis on the development of large, multicenter interventional trials for early childhood CF.

Main Results:

  • The precise impact of early treatment on delaying or preventing progressive lung disease in CF is not yet clearly defined.
  • Development of sensitive outcome measures is essential for conducting effective interventional studies in very young children.
  • New methodologies are emerging to facilitate large-scale clinical trials in infants and toddlers with CF.

Conclusions:

  • Early intervention strategies in cystic fibrosis require further investigation through well-designed clinical trials.
  • Advancements in outcome measures are critical for evaluating the efficacy of early treatments in preventing lung disease progression in infants.
  • Future research will focus on initiating interventions and slowing disease progression from the earliest stages of cystic fibrosis.

More Related Videos

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...